Vimarsana
Biggest News Aggregation in the World

Presenting Author News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Presenting Author. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Presenting Author Today - Breaking & Trending Today

EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress - Vimarsana News

EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress

SUZHOU, China and ROCKVILLE, Md., May 15, 2024 /PRNewswire/ -- Ascentage Pharma , a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B , and...

DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck - Vimarsana News

DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck

Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, today announced that new data supporting the utility of its DecisionDx-SCC test in patients...

Marin Fertility Center Presents Groundbreaking Study at the 2023 American ... - Vimarsana News

Marin Fertility Center Presents Groundbreaking Study at the 2023 American ...

Marin Fertility Center Presents Groundbreaking Study at the 2023 American ...

ESSA Pharma Inc. Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat - Vimarsana News

ESSA Pharma Inc. Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat

ESSA Pharma Inc. announced the presentation of updated dose escalation data from its Phase 1/2 study evaluating masofaniten in combination with enzalutamide at the 30th Annual Prostate Cancer...

SGLT2 inhibitors do not reduce 28-day mortality in hospitalized COVID-19 patients - Vimarsana News

SGLT2 inhibitors do not reduce 28-day mortality in hospitalized COVID-19 patients

Sodium glucose co-transporter-2 (SGLT2) inhibitors do not lead to lower 28-day all-cause mortality compared with usual care or placebo in patients hospitalized with COVID-19, according to late-breaking research presented in a Hot Line session today at ESC Congress 2023.